Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
LL-3737 residuesLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: hCAP-18 (precursor), CAMP, FALL-39
Three human wound healing trials. That is LL-37's clinical resume, and it is more than most antimicrobial peptides can claim. LL-37 is the only cathelicidin produced by the human body, a 37-amino-acid peptide your neutrophils release as a first-line defense against bacteria, viruses, and fungi. The Phase IIb HEAL trial (148 patients) confirmed wound healing activity at the 0.5 mg/mL dose, with a 6x higher healing rate constant versus placebo. Community users inject it subcutaneously for biofilm infections and immune support, though every clinical trial to date used topical application. That route gap matters.
LL-37 (also called hCAP-18 in its precursor form, molecular weight 4493.3 Da) is a 37-amino-acid cationic antimicrobial peptide produced by neutrophils, epithelial cells, and barrier tissues. The Phase IIb HEAL trial (PMC9298190, 2022, n=148) produced the strongest clinical signal: healing rate constant 6 times higher than placebo in venous leg ulcers (P=0.003). Neutrophils, epithelial cells, and barrier tissues all produce it. Its amphipathic alpha-helical structure lets it punch through bacterial membranes on contact, and it penetrates the extracellular polymeric matrix of biofilms, the protective slime that makes embedded bacteria up to 1,000 times more antibiotic-resistant. Community use centers on subcutaneous injection at 50 to 200 mcg daily for chronic infections, wound healing, and immune support. The practical challenge is pharmacological. Systemic half-life in serum runs under 30 minutes, and plasma proteins actively inhibit both antimicrobial and anticancer activity. The working theory is that SC injection creates a local depot effect rather than meaningful systemic distribution. Two additional human trials round out the clinical picture. A Phase I/II study [1] showed positive results for venous leg ulcers. A separate RCT for diabetic foot ulcers (Springer 2023) confirmed safety with a positive healing trend. All three trials used topical application. No human SC pharmacokinetic data exists.
Proteinase 3 cleaves LL-37 from its precursor protein hCAP-18 inside neutrophil granules. The released peptide carries a net positive charge that drives electrostatic attraction to negatively charged bacterial membranes. Once bound, LL-37's hydrophobic face inserts into the lipid bilayer. It forms toroidal pores or carpets the membrane surface until structural integrity collapses. Bacterial lysis follows within minutes. Biofilm disruption works through a different path. LL-37 penetrates the extracellular polymeric matrix surrounding embedded bacteria. It disrupts quorum sensing, the chemical signaling bacteria use to coordinate group defense. Conventional antibiotics often cannot breach this matrix at all; LL-37 reaches bacteria that have been hiding from treatment for months. Beyond direct killing, LL-37 binds lipopolysaccharide and lipoteichoic acid. This neutralizes bacterial endotoxins before they trigger excessive inflammatory signaling. It also activates formyl peptide receptor-like 1 (FPRL1), pulling neutrophils, monocytes, and T-cells toward infection sites. Wound healing gets a separate boost through VEGF upregulation (angiogenesis), keratinocyte migration, and collagen deposition. Dose determines the inflammatory direction. Low concentrations suppress pro-inflammatory cytokine release from macrophages. Higher concentrations amplify inflammation. That concentration-dependent switch makes dose selection more important with LL-37 than with most peptides in the immune category.
Wound healing is the only human-trial-supported use (topical application). Phase I/II RCT [1] showed positive results for hard-to-heal venous leg ulcers. Phase IIb HEAL trial (PMC9298190, n=148) missed primary endpoint but 0.5 mg/mL arm had 6× higher healing rate constant vs placebo (P=0.003). Diabetic foot ulcer RCT (Springer 2023) found safe with positive healing trend. No SC injection human PK or efficacy data exists.
Phase IIb HEAL trial: Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers (PMC9298190, 2022, n=148)
All human trials used topical application, not SC injection. No human SC PK/PD data. Activity inhibited in human plasma by serum proteins. Mixed oncology profile (pro-tumor in 7 cancer types vs anti-tumor in colon/gastric/hematologic). No regulatory approval for any route.
Used primarily for chronic/recurrent infections, biofilm disruption, immune support, and wound healing via SC injection. Daily dosing is the universal community standard: 2×/week site frequencies are not used. Regarded as a niche but potent tool; less popular than BPC-157/TB-500 for wound healing.
Science supports wound healing via topical application; community uses SC injection for wound healing + infections + immune support. Mechanisms (local AMP activity, biofilm disruption) are consistent across both, but routes differ and SC bioavailability data is absent. Community daily dosing is pharmacologically more defensible than site's 2×/week given the <30 min systemic half-life.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Daily |
| Moderate | 100mcg | Daily |
| Aggressive | 200mcg | Daily |
Reconstitution math for a 5 mg vial with 2 mL bacteriostatic water: total volume is 200 units on an insulin syringe. Each unit delivers 25 mcg. So 50 mcg is 2 units, 100 mcg is 4 units, 125 mcg is 5 units, 200 mcg is 8 units. Start at 50 mcg daily (2 units) for the first week regardless of experience level. LL-37 is potent enough that skipping the titration week creates unnecessary risk. The dosing frequency listed in most structured references is 2 to 3 times per week. Community consensus and pharmacological logic both point to daily dosing. With a systemic half-life under 30 minutes, twice-weekly injections leave zero circulating peptide between doses. Source matters more with LL-37 than many peptides. Request HPLC purity certificates showing 98% or higher and mass spectrometry confirmation of the correct molecular weight (4493.3 Da). Endotoxin (LAL) test certificates are non-negotiable for any antimicrobial peptide. Verify the vendor uses solid-phase peptide synthesis, not E. coli expression systems that carry LPS contamination risk. Reconstituted vials go in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks. Discard if you see particles, cloudiness, or color change.
LL-37 is an endogenous human peptide but is produced locally at mucosal surfaces, not circulating systemically. Repeated SC injection exposes the immune system to LL-37 in a context where it may trigger ADA (anti-drug antibody) formation, potentially reducing efficacy or causing hypersensitivity. The documented pro-tumor and pro-inflammatory risks at higher concentrations make continuous unmonitored use unwise. Community consensus of 4–6 week cycles reflects precautionary cycling pending better long-term data.
Or use the universal Peptide Calculator for any peptide.
Expected: Reduced frequency/severity of recurrent infections; enhanced innate immune response at local tissue level
Monitor: Monitor injection site reactions. If flu-like symptoms beyond day 5, reduce dose.
Gather supplies: LL-37 vial (5 mg lyophilized), bacteriostatic water, alcohol swabs, 29 to 31 gauge insulin syringe (0.5 mL or 1 mL).
Reconstitute by adding 2 mL of bacteriostatic water to the 5 mg vial. Direct the stream against the glass wall, not directly onto the powder. Swirl gently until fully dissolved. Do not shake. This gives you 25 mcg per unit on an insulin syringe.
For a 50 mcg beginner dose, pull to the 2 unit mark. For 100 mcg (moderate), pull to 4 units. For 125 mcg (intermediate wound healing protocol), pull to 5 units. For 200 mcg (advanced), pull to 8 units.
Pinch a fold of skin on the abdomen (avoiding 2 inches around the navel) or outer thigh. Insert the needle at a 45 degree angle into the subcutaneous layer.
Rotate injection sites with each dose.
Dose daily, not 2 to 3 times per week. The sub-30-minute systemic half-life makes daily dosing the pharmacologically sound choice.
Store the reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Discard after 4 weeks or if the solution changes appearance.
0.5–1.6 mg/mL concentration applied directly to wound 2×/week vs 50–200 mcg SC daily
Topical is the ONLY route with human trial data. Requires pharmaceutical-grade formulation (0.5–1.6 mg/mL in cream/gel vehicle). Research vendor lyophilized powder dissolved in water or saline is not equivalent to trial formulations. No self-compounded topical protocols validated in community.
Complementary immune coverage: LL-37 targets innate immunity (direct antimicrobial, AMP activity); TA-1 targets adaptive immunity (T-cell differentiation, TLR signaling). Frequently combined for broad immune support.
LL-37 50–125 mcg SC daily + TA-1 1.5 mg SC 2×/week
Most commonly cited wound healing stack. BPC-157 promotes angiogenesis and tissue repair via systemic distribution; LL-37 provides local antimicrobial + wound healing at site. Combined effect on wound closure and infection control.
LL-37 100–125 mcg SC daily + BPC-157 250–500 mcg SC daily near wound site
Anti-inflammatory complement to LL-37. Useful when LL-37-driven immune activation is too strong or wound has significant inflammatory component. KPV counterbalances LL-37's pro-inflammatory risk at higher doses.
LL-37 100 mcg SC daily + KPV 500 mcg–1 mg SC daily. Use with caution; monitor for immunosuppression.
Blunt LL-37 immune-stimulating effects. Corticosteroids suppress the innate immune pathways LL-37 activates, negating therapeutic benefit.
Do not combineLL-37 binds heparin-binding sites; potential interaction with heparin and related anticoagulants. Monitor coagulation parameters.
Reduces LL-37 immune-modulating effects. Concurrent use undermines both agents' therapeutic intent.
Pricing updated 2026-04-09
LL-37 becomes pro-inflammatory at tissue concentrations at or above 10 mcg/mL. That makes it one of the few peptides where overdosing doesn't just waste product; it actively reverses the therapeutic goal. High-grade fever, pronounced systemic inflammation, and immune flare are all possible above this threshold. Pro-tumor activity has been documented across seven cancer types (lung, ovarian, breast, prostate, melanoma, liver, skin SCC). Anyone with active malignancy or raised cancer risk should treat this as a hard contraindication. Published side effects from the three human trials (all topical application) were mild: local irritation at the wound site with no systemic adverse events. SC injection side effects come from community reports, not controlled trials. Injection site pain and redness are the most commonly reported issues, particularly at doses above 100 mcg. Community sources describe localized nodules that can persist for 2 to 3 days when injection technique is poor or sites aren't rotated. Flu-like symptoms during the first 3 to 5 days reflect immune activation from macrophage stimulation and cytokine release. Most reports indicate these resolve by day 5 to 7. Persistent flu-like symptoms beyond day 5 or any high-grade fever warrant immediate dose reduction or cessation. LL-37 is raised in psoriatic skin lesions and induces Type I interferon relevant to systemic lupus erythematosus. Anyone with active psoriasis, lupus, or other autoimmune conditions should not use this peptide. Worsening of autoimmune flares has been reported; stop immediately if any flare occurs. The systemic half-life sits under 30 minutes, and plasma proteins inhibit LL-37 activity. This creates genuine uncertainty about whether SC injection achieves tissue concentrations sufficient for antimicrobial effect beyond the local injection site. Contraindications: pregnancy or breastfeeding (no safety data), known hypersensitivity to cathelicidin-derived peptides, active autoimmune conditions (psoriasis, lupus), active malignancy, and children under 18. When to seek medical attention: high-grade fever, signs of excessive immune activation, any autoimmune flare, or persistent injection site nodules lasting beyond 3 days.
Verify LL-37 dosing and safety with a second opinion
LL-37 is a 37-amino-acid AMP with an amphipathic alpha-helical structure critical for bioactivity. Proper folding and purity are essential: truncated or misfolded product may be biologically inactive or cytotoxic. Endotoxin contamination is a significant risk in AMP synthesis (LPS is a frequent contaminant in bacterial expression systems). Plasma protein inhibition means even correctly synthesized product may have limited systemic activity. No FDA-approved SC formulation exists as a quality benchmark.
| Test | When | Target |
|---|---|---|
| Comprehensive metabolic panel (CMP) | Baseline before start; repeat at 4 weeks if using >100 mcg/day | — |
| CBC with differential | Baseline; optional at 4 weeks for immune monitoring | — |
| C-reactive protein (CRP) / ESR | Baseline; repeat at 2 weeks if flu-like symptoms present | — |
| Wound measurement (if wound healing indication) | Weekly during treatment cycle: photograph and measure wound dimensions | ≥25% wound area reduction by week 4 is a reasonable efficacy threshold based on clinical trial outcomes |
Rule out any hepatic or renal effects from immune activation; baseline safety check
Track immune cell counts, particularly neutrophils and lymphocytes, as markers of LL-37's immunomodulatory effect
Confirm immune activation is resolving, not escalating. Persistently elevated CRP with symptoms warrants dose reduction or cessation.
Only objective way to assess efficacy. Clinical trials (PMID 25041740) used wound area reduction as primary endpoint.
Treatment initiation. LL-37 begins circulating and interacting with target tissues. Injection site redness or mild soreness is common at this stage. No noticeable systemic changes yet.
Early immune activation. Innate immune cell recruitment increases at infection or wound sites. Some users report reduced redness or drainage from chronic wounds. Mild flu-like symptoms may occur as immune activity ramps up.
Antimicrobial and wound-healing effects become more apparent. Biofilm disruption allows better immune clearance of chronic infections. Wound granulation tissue formation and re-epithelialization may accelerate.
Peak therapeutic window. Measurable improvements in wound closure, reduced bacterial load at infection sites, and stronger innate immune markers. Cycle typically ends here: reassess before continuing.
Days 1 to 3 (Initiation): Local antimicrobial peptide activity begins at the injection site. Neutrophils and monocytes start migrating toward the area through FPRL1 activation. Expect injection site redness and mild soreness. Some users report mild fatigue as the immune system ramps up. No systemic changes at this stage. Days 4 to 10 (Early immune activation): Innate immune cell recruitment picks up at infection or wound sites. LPS neutralization and cytokine modulation are underway. Flu-like symptoms typically peak during this window, then fade. Some users notice reduced drainage from chronic wounds or improved skin at wound edges. Most flu-like symptoms (fatigue, mild fever, body aches) clear by day 7. Weeks 2 to 3 (Antimicrobial and wound healing effect): Biofilm disruption, if applicable, starts improving immune clearance of entrenched infections. Keratinocyte migration and angiogenesis through VEGF upregulation accelerate wound closure. Visible improvements in wound tissue quality or reduced infection signs are commonly reported. Earlier immune activation symptoms have typically resolved. Weeks 4 to 6 (Peak therapeutic window): Clinical trials achieved maximum wound healing response by weeks 12 to 13 with topical application. SC injection timelines run shorter given the local-only mechanism hypothesis. Most users report measurable changes in wound healing or infection status by this point. Cycles typically end here; reassess before extending.
Local AMP activity at injection site. Neutrophil and monocyte chemotaxis via FPRL1 activation.
Injection site redness, mild soreness. No systemic changes. Some report mild fatigue as immune system activates.
Innate immune cell recruitment increases at infection/wound sites. LPS neutralization and cytokine modulation.
Flu-like symptoms peak then subside. Some report reduced drainage from chronic wounds or improved skin around wound edges.
Biofilm disruption (if applicable) improves immune clearance. Keratinocyte migration and angiogenesis via VEGF upregulation accelerate wound closure.
Visible improvement in wound tissue quality or reduced infection signs reported. Immune activation symptoms resolve.
Maximum wound healing response in clinical trials achieved by weeks 12–13 (topical studies). SC injection timeline shorter given local-only mechanism hypothesis.
Most users report noticeable changes in wound healing or infection status by week 4–6. Cycle typically ends here; reassess before extending.
Source: Serum t1/2 <30 minutes (rapid proteolytic degradation); wound fluid stability 4-6 hours (PMID 21547341)
Loading the interactive decay curve.
LL-37 has no FDA approval for any indication or route of administration. It carries a preclinical regulatory status. The three completed human trials (Phase I/II for venous leg ulcers, Phase IIb HEAL trial, diabetic foot ulcer RCT) all used topical formulations under investigational protocols. Research peptide vendors sell LL-37 labeled "for research purposes only" or "not for human consumption." No compounding pharmacy protocols exist for systemic LL-37, and no FDA-approved SC formulation provides a quality benchmark. Athletes should verify WADA status before use. Antimicrobial peptides are not specifically listed on the WADA prohibited list, but peptide hormones and growth factors are a monitored category. Consult a sports medicine physician if competition testing applies. This content is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide.
Peptide Schedule Research TeamReviewed Apr 20269 Citations
